Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Mereo BioPharma Group plcNASDAQ: MREO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$304.49K, compared with -$271.04K a year earlier. Trailing-twelve-month gross profit was -$528.63K. Over 3 fiscal years it compounded at +12.5% a year.

Context

  • Gross profit amounted to 73.4% of revenue in FY2025.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$304.49K or moves back toward the trailing-twelve-month quarterly average of -$132.16K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$304.49K+48.5% QoQ
Last fiscal yearDec 2025
$367K+133.7% YoY
LTMMar 2026
-$528.63K+51.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.3%——
1 year+133.7%——
3-year CAGR+12.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
367K USD
Year-over-year change
+133.7%
4-year CAGR
-65.2%

Gross Profit vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +51.3% is the 2nd highest of 6, against a peer median of -36.4%.
  • Gross profit amounts to 105.7% of revenue for MREO, versus a peer median of 94.9%.
MREO Competitors
Gross Profit for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRQRProQR Therapeutics N.V.LTM Mar 2026€12.06M EUR-36.4%+52.2%89.7%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%100.0%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K USD—-62.8%66.4%
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$66.6K USD———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$79K USD———
MREOMereo BioPharma Group plcLTM Mar 2026-$528.63K USD+51.3%+12.5%105.7%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$546K USD———
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$866K USD+97.1%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$42.41M USD-4.9%——
IMMPImmutep LimitedFY2025-A$56.37M AUD-49.5%—1117.6%
Peer median (excluding MREO) —-36.4%-3.2%94.9%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.